当前期刊: Journal of Cachexia, Sarcopenia and Muscle Go to current issue    加入关注   
显示样式:        排序: 导出
我的关注
我的收藏
您暂时未登录!
登录
  • Reference values for skeletal muscle mass and fat mass measured by bioelectrical impedance in 390 565 UK adults
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2020-01-13
    Mei‐Man Lee; Susan A. Jebb; Jason Oke; Carmen Piernas

    Loss of skeletal muscle mass (SMM) increases the risk of frailty and, together with excess fat mass (FM), is a risk factor for cardio‐metabolic disease. However, use of body composition measurements in nutritional surveillance and routine clinical practice is limited by the lack of reference data. Our aim was to produce age‐specific and sex‐specific reference values for SMM and FM in the White ethnic adult population in the UK. Secondary objectives were to examine the tracking over time using a subsample of the population with repeated measures of body composition and to assess the validity of these reference values in different ethnic subgroups.

    更新日期:2020-01-14
  • Paediatric reference values for total psoas muscle area
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2020-01-09
    Eberhard Lurz; Hiten Patel; Gerald Lebovic; Claudia Quammie; Jessica P. Woolfson; Manuela Perez; Amanda Ricciuto; Paul W. Wales; Binita M. Kamath; Govind B. Chavhan; Peter Jüni; Vicky L. Ng

    Sarcopenia, the unintentional loss of skeletal muscle mass, is associated with poor outcomes in adult patient populations. In adults, sarcopenia is often ascertained by cross‐sectional imaging of the psoas muscle area (PMA). Although children with chronic medical illnesses may be at increased risk for muscle loss because of nutritional deficiencies, physical deconditioning, endocrine anomalies, and systemic inflammation, consistent quantitative definitions for sarcopenia in children are lacking. We aimed to generate paediatric reference values for PMA at two intervertebral lumbar levels, L3–4 and L4–5.

    更新日期:2020-01-11
  • Nutrition interventions to treat low muscle mass in cancer
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2020-01-08
    Carla M. Prado; Sarah A. Purcell; Alessandro Laviano

    Many patients with cancer experience poor nutritional status, which detrimentally impacts clinical outcomes. Poor nutritional status in cancer is primarily manifested by severe muscle mass (MM) depletion, which may occur at any stage (from curative to palliative) and often co‐exists with obesity. The objective of this article was to discuss gaps and opportunities related to the role of nutrition in preventing and reversing low MM in cancer. It also provides a narrative review of relevant nutritional interventions for patients capable of oral intake. The impact of nutrition interventions to prevent/treat low MM in cancer is not well understood, potentially due to the limited number of studies and of clinically viable, accurate body composition assessment tools. Additionally, the type of study designs, inclusion criteria, length of intervention, and choice of nutritional strategies have not been optimal, likely underestimating the anabolic potential of nutrition interventions. Nutrition studies are also often of short duration, and interventions that adapt to the metabolic and behavioural changes during the clinical journey are needed. We discuss energy requirements (25–30 kcal/kg/day) and interventions of protein (1.0–1.5 g/kg/day), branched‐chain amino acids (leucine: 2–4 g/day), β‐hydroxy β‐methylbutyrate (3 g/day), glutamine (0.3 g/kg/day), carnitine (4–6 g/day), creatine (5 g/day), fish oil/eicosapentanoic acid (2.0–2.2 g/day EPA and 1.5 g/day DHA), vitamin/minerals (e.g. vitamin D: 600–800 international units per day), and multimodal approaches (nutrition, exercise, and pharmaceutical) to countermeasure low MM in cancer. Although the evidence is variable by modality type, interventions were generally not specifically studied in the context of cancer. Understanding patients' nutritional requirements could lead to targeted prescriptions to prevent or attenuate low MM in cancer, with the overall aim of minimizing muscle loss during anti‐cancer therapy and maximizing muscle anabolism during recovery. It is anticipated that this will, in turn, improve overall health and prognostication including tolerance to treatment and survival. However, oncology‐specific interventions with more robust study designs are needed to facilitate these goals.

    更新日期:2020-01-09
  • Comparison of multidimensional frailty score, grip strength, and gait speed in older surgical patients
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2020-01-08
    Jung‐Yeon Choi; Kwang‐il Kim; YoungRok Choi; Sang‐Hoon Ahn; Eunyoung Kang; Heung‐Kwon Oh; Duck‐Woo Kim; Eun‐Kyu Kim; Yoo‐Seok Yoon; Sung‐Bum Kang; Hyung‐Ho Kim; Ho‐Seong Han; Cheol‐Ho Kim

    Frail older adults are at increased risk of post‐operative morbidity compared with robust counterparts. Simple methods testing frailty such as grip strength or gait speed have shown promising results for predicting post‐operative outcome, but there is a debate regarding the most appropriate and precise frailty assessment method. We compared the predictive value of multidimensional frailty score (MFS) with grip strength, gait speed, or conventional risk stratification tool for predicting post‐operative complications in older surgical patients.

    更新日期:2020-01-08
  • Biomarkers of sarcopenia in very old patients with hip fracture
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2020-01-08
    Carmen Sánchez‐Castellano; Sagrario Martín‐Aragón; Paloma Bermejo‐Bescós; Nieves Vaquero‐Pinto; Carmen Miret‐Corchado; Ana Merello de Miguel; Alfonso José Cruz‐Jentoft

    Hip fracture is both a cause and a consequence of sarcopenia. Older persons with sarcopenia have an increased risk of falling, and the prevalence of sarcopenia may be increased in those who suffer a hip fracture. The aim of this study was to explore potential biomarkers (neuromuscular and peripheral pro‐inflammatory and oxidative stress markers) that may be associated with sarcopenia in very old persons with hip fracture.

    更新日期:2020-01-08
  • Which one came first: movement behavior or frailty? A cross‐lagged panel model in the Toledo Study for Healthy Aging
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2020-01-08
    Asier Mañas; Borja del Pozo‐Cruz; Irene Rodríguez‐Gómez; José Losa‐Reyna; Leocadio Rodríguez‐Mañas; Francisco J. García‐García; Ignacio Ara

    There has been limited longitudinal assessment of the relationship between moderate‐to‐vigorous physical activity (MVPA) and sedentary behaviour (SB) with frailty, and no studies have explored the possibility of reverse causality. This study aimed to determine the potential bidirectionality of the relationship between accelerometer‐assessed MVPA, SB, and frailty over time in older adults.

    更新日期:2020-01-08
  • p300 and cAMP response element‐binding protein‐binding protein in skeletal muscle homeostasis, contractile function, and survival
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2020-01-03
    Kristoffer Svensson; Samuel A. LaBarge; Abha Sathe; Vitor F. Martins; Shahriar Tahvilian; Jennifer M. Cunliffe; Roman Sasik; Sushil K. Mahata; Gretchen A. Meyer; Andrew Philp; Larry L. David; Samuel R. Ward; Carrie E. McCurdy; Joseph E. Aslan; Simon Schenk

    Reversible ε‐amino acetylation of lysine residues regulates transcription as well as metabolic flux; however, roles for specific lysine acetyltransferases in skeletal muscle physiology and function are unknown. In this study, we investigated the role of the related acetyltransferases p300 and cAMP response element‐binding protein‐binding protein (CBP) in skeletal muscle transcriptional homeostasis and physiology in adult mice.

    更新日期:2020-01-04
  • Sarcopenia, long‐term conditions, and multimorbidity: findings from UK Biobank participants
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2019-12-30
    Richard M. Dodds; Antoneta Granic; Sian M. Robinson; Avan A. Sayer

    Sarcopenia, the loss of muscle strength and mass, predicts adverse outcomes and becomes common with age. There is recognition that sarcopenia may occur at younger ages in those with long‐term conditions (LTCs) as well as those with multimorbidity (the presence of two or more LTCs), but their relationships have been little explored. Our aims were to describe the prevalence of sarcopenia in UK Biobank, a large sample of men and women aged 40–70 years, and to explore relationships with different categories of LTCs and multimorbidity.

    更新日期:2019-12-30
  • Longitudinal serum biomarker screening identifies malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2019-12-27
    Mirko Signorelli; Burcu Ayoglu; Camilla Johansson; Hanns Lochmüller; Volker Straub; Francesco Muntoni; Erik Niks; Roula Tsonaka; Anja Persson; Annemieke Aartsma‐Rus; Peter Nilsson; Cristina Al‐Khalili Szigyarto; Pietro Spitali

    Duchenne muscular dystrophy (DMD) is a fatal disease for which no cure is available. Clinical trials have shown to be largely underpowered due to inter‐individual variability and noisy outcome measures. The availability of biomarkers able to anticipate clinical benefit is highly needed to improve clinical trial design and facilitate drug development.

    更新日期:2019-12-29
  • Grip strength mediates the relationship between muscle mass and frailty
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2019-12-26
    Yu‐Ri Choe; Ju‐Ri Jeong; Yeon‐Pyo Kim

    Although sarcopenia and frailty are important diseases in geriatrics, few studies have investigated the association between the two diseases. Thus, this study aimed to examine the relationship between two components of sarcopenia (muscle mass and muscle function) and frailty.

    更新日期:2019-12-27
  • Characteristics of sarcopenia by European consensuses and a phenotype score
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2019-12-21
    Il‐Young Jang; Eunju Lee; Heayon Lee; Hyungchul Park; Sunyoung Kim; Kwang‐il Kim; Hee‐Won Jung; Dae Hyun Kim

    We aimed to assess the clinical characteristics of sarcopenia by the original and revised European Working Group on Sarcopenia in Older People (EWGSOP 1 and 2), and to propose a new sarcopenia phenotype score (SPS) to improve relevance of clinical outcomes.

    更新日期:2019-12-21
  • Chronic heart failure with diabetes mellitus is characterized by a severe skeletal muscle pathology
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2019-12-21
    Jack O. Garnham; Lee D. Roberts; Ever Espino‐Gonzalez; Anna Whitehead; Peter P. Swoboda; Aaron Koshy; John Gierula; Maria F. Paton; Richard M. Cubbon; Mark T. Kearney; Stuart Egginton; T. Scott Bowen; Klaus K. Witte

    Patients with coexistent chronic heart failure (CHF) and diabetes mellitus (DM) demonstrate greater exercise limitation and worse prognosis compared with CHF patients without DM, even when corrected for cardiac dysfunction. Understanding the origins of symptoms in this subgroup may facilitate development of targeted treatments. We therefore characterized the skeletal muscle phenotype and its relationship to exercise limitation in patients with diabetic heart failure (D‐HF).

    更新日期:2019-12-21
  • Uniform sarcolemmal dystrophin expression is required to prevent extracellular microRNA release and improve dystrophic pathology
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2019-12-17
    Tirsa L.E. van Westering; Yulia Lomonosova; Anna M.L. Coenen‐Stass; Corinne A. Betts; Amarjit Bhomra; Margriet Hulsker; Lucy E. Clark; Graham McClorey; Annemieke Aartsma‐Rus; Maaike van Putten; Matthew J.A. Wood; Thomas C. Roberts

    Duchenne muscular dystrophy (DMD) is a fatal muscle‐wasting disorder caused by genetic loss of dystrophin protein. Extracellular microRNAs (ex‐miRNAs) are putative, minimally invasive biomarkers of DMD. Specific ex‐miRNAs (e.g. miR‐1, miR‐133a, miR‐206, and miR‐483) are highly up‐regulated in the serum of DMD patients and dystrophic animal models and are restored to wild‐type levels following exon skipping‐mediated dystrophin rescue in mdx mice. As such, ex‐miRNAs are promising pharmacodynamic biomarkers of exon skipping efficacy. Here, we aimed to determine the degree to which ex‐miRNA levels reflect the underlying level of dystrophin protein expression in dystrophic muscle.

    更新日期:2019-12-19
  • Identification of microRNAs in skeletal muscle associated with lung cancer cachexia
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2019-12-11
    Wouter R.P.H. van de Worp; Annemie M.W.J. Schols; Anne‐Marie C. Dingemans; Céline M.H. Op den Kamp; Juliette H.R.J. Degens; Marco C.J.M. Kelders; Susan Coort; Henry C. Woodruff; Gueorqui Kratassiouk; Annick Harel‐Bellan; Jan Theys; Ardy van Helvoort; Ramon C.J. Langen

    Cachexia, highly prevalent in patients with non‐small cell lung cancer (NSCLC), impairs quality of life and is associated with reduced tolerance and responsiveness to cancer therapy and decreased survival. MicroRNAs (miRNAs) are small non‐coding RNAs that play a central role in post‐transcriptional gene regulation. Changes in intramuscular levels of miRNAs have been implicated in muscle wasting conditions. Here, we aimed to identify miRNAs that are differentially expressed in skeletal muscle of cachectic lung cancer patients to increase our understanding of cachexia and to allow us to probe their potential as therapeutic targets.

    更新日期:2019-12-13
  • Relationship between pulmonary function and physical performance among community‐living people: results from Look‐up 7+ study
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2019-12-04
    Francesco Landi, Sara Salini, Maria Beatrice Zazzara, Anna Maria Martone, Sofia Fabrizi, Mariangela Bianchi, Matteo Tosato, Anna Picca, Riccardo Calvani, Emanuele Marzetti

    While respiratory muscle strength is recognized to decline with aging process, the relationship between sarcopenia and pulmonary function remains to be studied. The present study was undertaken to provide a better insight into the comprehension of the relationship between pulmonary function and muscle function (strength and physical performance) using an unselected sample of subjects assessed during the Longevity Check‐up 7+ project.

    更新日期:2019-12-04
  • Muscle mass, strength, and physical performance predicting activities of daily living: a meta‐analysis
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2019-12-01
    Daniel X.M. Wang, Jessica Yao, Yasar Zirek, Esmee M. Reijnierse, Andrea B. Maier

    Background

    更新日期:2019-12-02
  • Effects of aerobic and inspiratory training on skeletal muscle microRNA‐1 and downstream‐associated pathways in patients with heart failure
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2019-11-19
    Ligia M. Antunes‐Correa, Patricia F. Trevizan, Aline V.N. Bacurau, Larissa Ferreira‐Santos, João L.P. Gomes, Ursula Urias, Patricia A. Oliveira, Maria Janieire N.N. Alves, Dirceu R. de Almeida, Patricia C. Brum, Edilamar M. Oliveira, Ludhmila Hajjar, Roberto Kalil Filho, Carlos Eduardo Negrão

    The exercise intolerance in chronic heart failure with reduced ejection fraction (HFrEF) is mostly attributed to alterations in skeletal muscle. However, the mechanisms underlying the skeletal myopathy in patients with HFrEF are not completely understood. We hypothesized that (i) aerobic exercise training (AET) and inspiratory muscle training (IMT) would change skeletal muscle microRNA‐1 expression and downstream‐associated pathways in patients with HFrEF and (ii) AET and IMT would increase leg blood flow (LBF), functional capacity, and quality of life in these patients.

    更新日期:2019-11-20
  • Muscle‐specific changes in protein synthesis with aging and reloading after disuse atrophy
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2019-07-16
    Benjamin F. Miller, Leslie M. Baehr, Robert V. Musci, Justin J. Reid, Frederick F. Peelor, Karyn L. Hamilton, Sue C. Bodine

    Successful strategies to halt or reverse sarcopenia require a basic understanding of the factors that cause muscle loss with age. Acute periods of muscle loss in older individuals have an incomplete recovery of muscle mass and strength, thus accelerating sarcopenic progression. The purpose of the current study was to further understand the mechanisms underlying the failure of old animals to completely recover muscle mass and function after a period of hindlimb unloading.

    更新日期:2019-11-18
  • Clinical and biological characterization of skeletal muscle tissue biopsies of surgical cancer patients
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2019-07-15
    Ana Anoveros‐Barrera, Amritpal S. Bhullar, Cynthia Stretch, Nina Esfandiari, Abha R. Dunichand‐Hoedl, Karen J.B. Martins, David Bigam, Rachel G. Khadaroo, Todd McMullen, Oliver F. Bathe, Sambasivarao Damaraju, Richard J. Skipworth, Charles T. Putman, Vickie E. Baracos, Vera C. Mazurak

    Researchers increasingly use intraoperative muscle biopsy to investigate mechanisms of skeletal muscle atrophy in patients with cancer. Muscles have been assessed for morphological, cellular, and biochemical features. The aim of this study was to conduct a state‐of‐the‐science review of this literature and, secondly, to evaluate clinical and biological variation in biopsies of rectus abdominis (RA) muscle from a cohort of patients with malignancies.

    更新日期:2019-11-18
  • Mice with myocyte deletion of vitamin D receptor have sarcopenia and impaired muscle function
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2019-06-21
    Christian M. Girgis, Kuan Minn Cha, Benjamin So, Michael Tsang, Jennifer Chen, Peter J. Houweling, Aaron Schindeler, Rebecca Stokes, Michael M. Swarbrick, Frances J. Evesson, Sandra T. Cooper, Jenny E. Gunton

    It has long been recognized that vitamin D deficiency is associated with muscle weakness and falls. Vitamin D receptor (VDR) is present at very low levels in normal muscle. Whether vitamin D plays a direct role in muscle function is unknown and is a subject of hot debate. Myocyte‐specific deletion of VDR would provide a strategy to answer this question.

    更新日期:2019-11-18
  • The prognostic significance of weight loss in chronic obstructive pulmonary disease‐related cachexia: a prospective cohort study
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2019-06-17
    Hoi Yee Kwan, Matthew Maddocks, Claire M. Nolan, Sarah E. Jones, Suhani Patel, Ruth E. Barker, Samantha S.C. Kon, Michael I. Polkey, Paul Cullinan, William D.‐C. Man

    Cachexia is an important extra‐pulmonary manifestation of chronic obstructive pulmonary disease (COPD) presenting as unintentional weight loss and altered body composition. Previous studies have focused on the relative importance of body composition compared with body mass rather than the relative importance of dynamic compared with static measures. We aimed to determine the prevalence of cachexia and pre‐cachexia phenotypes in COPD and examine the associations between cachexia and its component features with all‐cause mortality.

    更新日期:2019-11-18
  • Vitamin D repletion ameliorates adipose tissue browning and muscle wasting in infantile nephropathic cystinosis‐associated cachexia
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2019-11-13
    Wai W. Cheung, Sheng Hao, Zhen Wang, Wei Ding, Ronghao Zheng, Alex Gonzalez, Jian‐Ying Zhan, Ping Zhou, Shiping Li, Mary C. Esparza, Hal M. Hoffman, Richard L. Lieber, Robert H. Mak

    Ctns−/− mice, a mouse model of infantile nephropathic cystinosis, exhibit hypermetabolism with adipose tissue browning and profound muscle wasting. Ctns−/− mice are 25(OH)D3 and 1,25(OH)2D3 insufficient. We investigated whether vitamin D repletion could ameliorate adipose tissue browning and muscle wasting in Ctns−/− mice.

    更新日期:2019-11-13
  • Derangements of amino acids in cachectic skeletal muscle are caused by mitochondrial dysfunction
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2019-11-13
    Thomas Kunzke, Achim Buck, Verena M. Prade, Annette Feuchtinger, Olga Prokopchuk, Marc E. Martignoni, Simone Heisz, Hans Hauner, Klaus‐Peter Janssen, Axel Walch, Michaela Aichler

    Cachexia is the direct cause of at least 20% of cancer‐associated deaths. Muscle wasting in skeletal muscle results in weakness, immobility, and death secondary to impaired respiratory muscle function. Muscle proteins are massively degraded in cachexia; nevertheless, the molecular mechanisms related to this process are poorly understood. Previous studies have reported conflicting results regarding the amino acid abundances in cachectic skeletal muscle tissues. There is a clear need to identify the molecular processes of muscle metabolism in the context of cachexia, especially how different types of molecules are involved in the muscle wasting process.

    更新日期:2019-11-13
  • mTORC 1 signalling is not essential for the maintenance of muscle mass and function in adult sedentary mice
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2019-11-07
    Alexander S. Ham, Kathrin Chojnowska, Lionel A. Tintignac, Shuo Lin, Alexander Schmidt, Daniel J. Ham, Michael Sinnreich, Markus A. Rüegg

    The balance between protein synthesis and degradation (proteostasis) is a determining factor for muscle size and function. Signalling via the mammalian target of rapamycin complex 1 (mTORC1) regulates proteostasis in skeletal muscle by affecting protein synthesis and autophagosomal protein degradation. Indeed, genetic inactivation of mTORC1 in developing and growing muscle causes atrophy resulting in a lethal myopathy. However, systemic dampening of mTORC1 signalling by its allosteric inhibitor rapamycin is beneficial at the organismal level and increases lifespan. Whether the beneficial effect of rapamycin comes at the expense of muscle mass and function is yet to be established.

    更新日期:2019-11-07
  • The relationship between the BMI‐adjusted weight loss grading system and quality of life in patients with incurable cancer
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2019-11-06
    Louise Daly, Ross Dolan, Derek Power, Éadaoin Ní Bhuachalla, Wei Sim, Marie Fallon, Samantha Cushen, Claribel Simmons, Donald C. McMillan, Barry J. Laird, Aoife Ryan

    Weight loss (WL) has long been recognized as an important factor associated with reduced quality of life (QoL) and reduced survival in patients with cancer. The body mass index (BMI)‐adjusted weight loss grading system (WLGS) has been shown to be associated with reduced survival. However, its impact on QoL has not been established. The aim of this study was to assess the relationship between this WLGS and QoL in patients with advanced cancer.

    更新日期:2019-11-06
  • Tracking muscle wasting and disease activity in facioscapulohumeral muscular dystrophy by qualitative longitudinal imaging
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2019-10-30
    Mauro Monforte, Francesco Laschena, Pierfrancesco Ottaviani, Maria Rosaria Bagnato, Anna Pichiecchio, Giorgio Tasca, Enzo Ricci

    Facioscapulohumeral muscular dystrophy (FSHD) is one of the most frequent late‐onset muscular dystrophies, characterized by progressive fatty replacement and degeneration involving single muscles in an asynchronous manner. With clinical trials at the horizon in this disease, the knowledge of its natural history is of paramount importance to understand the impact of new therapies. The aim of this study was to assess disease progression in FSHD using qualitative muscle magnetic resonance imaging, with a focus on the evolution of hyperintense lesions identified on short‐tau inversion recovery (STIR+) sequences, hypothesized to be markers of active muscle injury.

    更新日期:2019-11-01
  • Cancer cachexia: an orphan with a future.
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2019-03-29
    Mitja Lainscak,Giuseppe M C Rosano

    更新日期:2019-11-01
  • 更新日期:2019-11-01
  • Sedentary behaviour, physical activity, and sarcopenia among older adults in the TSHA: isotemporal substitution model.
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2019-03-29
    Juan Luis Sánchez-Sánchez,Asier Mañas,Francisco José García-García,Ignacio Ara,Jose Antonio Carnicero,Stefan Walter,Leocadio Rodríguez-Mañas

    BACKGROUND The associations between free-living physical activity (PA) and sedentary behaviour (SB) and sarcopenia in older people and its determinants are controversial. Self-reporting, the use of one-size-fits-all cut-points for intensity categorization when using accelerometers and the absence of a clear sarcopenia definition hampered explorations. The aim of this study is to describe the associations between objectively measured PA patterns and sarcopenia and its determinants. METHODS Subjects aged >65 with valid accelerometry and sarcopenia-related measures from Toledo Study of Healthy Aging (TSHA) were included. Muscle mass (MM) was estimated by dual-energy X-ray absorptiometry. Handgrip strength (HS) was measured by dynamometry. Physical performance assessment relied on gait speed (GS). Sarcopenia presence was ascertained using Foundation for the National Institutes of Health (FNIH) criteria. PA and SB were estimated by ActiTrainer worn for 1 week and classified into time spent in SB and different PA intensity bands [light PA (LPA) and moderate-to-vigorous PA (MVPA)] using age-specific cut-points. Different multivariate linear and logistic regression models [(i) single-parameter, (ii) partition, and (iii) isotemporal substitution models] were used for estimating associations between PA, SB, and sarcopenia determinants and sarcopenia rates, respectively. All models adjusted for age, sex, co-morbidities (Charlson index), and functional ability (Katz and Lawton indexes). RESULTS Five hundred twelve subjects from the TSHA had available data (78.08 ± 5.71 years of age; 54.3% women). FNIH sarcopenia assessment was performed in 497 subjects (23.3% were sarcopenic). In the linear regression, the single-parameter model showed an association between MVPA and all sarcopenia determinants. In the partition model, MVPA was associated with greater MM and GS. The isotemporal substitution showed that reallocating 1 h/day of MVPA displacing SB was associated with greater values in MM [β = 0.014; 95% confidence interval (CI) = 0.004, 0.024; P < 0.01], GS (β = 0.082; 95% CI = 0.054, 0.110; P < 0.001), and HS (β = 0.888; 95% CI = 0.145, 1.631; P < 0.05). In the logistic regression, the single-parameter model yielded a significant association between 1 h/day increase in MVPA and sarcopenia reduction [odds ratio (OR) = 0.522; 95% CI = 0.367, 0.726; P < 0.001], as did the partition model (OR = 0.555; 95% CI = 0.376, 0.799; P < 0.01). The reallocation of 1 h/day SB only yielded a significant lower sarcopenia risk by almost 50% when it was substituted with MVPA, whereas the substitution of 15 min/day yielded a significant lower sarcopenia risk by 15% (P < 0.001) but did not show any association when it was substituted with LPA. CONCLUSIONS An increase in MVPA replacing SB and LPA was associated with a reduction in sarcopenia prevalence and better performance across its determinants (MM, GS, and HS). LPA did not show any significant effect.

    更新日期:2019-11-01
  • GLIM criteria for the diagnosis of malnutrition - A consensus report from the global clinical nutrition community.
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2019-03-29
    T Cederholm,G L Jensen,M I T D Correia,M C Gonzalez,R Fukushima,T Higashiguchi,G Baptista,R Barazzoni,R Blaauw,A J S Coats,A N Crivelli,D C Evans,L Gramlich,V Fuchs-Tarlovsky,H Keller,L Llido,A Malone,K M Mogensen,J E Morley,M Muscaritoli,I Nyulasi,M Pirlich,V Pisprasert,M A E de van der Schueren,S Siltharm,P Singer,K Tappenden,N Velasco,D Waitzberg,P Yamwong,J Yu,A Van Gossum,C Compher,

    RATIONALE This initiative is focused on building a global consensus around core diagnostic criteria for malnutrition in adults in clinical settings. METHODS In January 2016, the Global Leadership Initiative on Malnutrition (GLIM) was convened by several of the major global clinical nutrition societies. GLIM appointed a core leadership committee and a supporting working group with representatives bringing additional global diversity and expertise. Empirical consensus was reached through a series of face-to-face meetings, telephone conferences, and e-mail communications. RESULTS A two-step approach for the malnutrition diagnosis was selected, i.e., first screening to identify "at risk" status by the use of any validated screening tool, and second, assessment for diagnosis and grading the severity of malnutrition. The malnutrition criteria for consideration were retrieved from existing approaches for screening and assessment. Potential criteria were subjected to a ballot among the GLIM core and supporting working group members. The top five ranked criteria included three phenotypic criteria (weight loss, low body mass index, and reduced muscle mass) and two etiologic criteria (reduced food intake or assimilation, and inflammation or disease burden). To diagnose malnutrition at least one phenotypic criterion and one etiologic criterion should be present. Phenotypic metrics for grading severity as Stage 1 (moderate) and Stage 2 (severe) malnutrition are proposed. It is recommended that the etiologic criteria be used to guide intervention and anticipated outcomes. The recommended approach supports classification of malnutrition into four etiology-related diagnosis categories. CONCLUSION A consensus scheme for diagnosing malnutrition in adults in clinical settings on a global scale is proposed. Next steps are to secure further collaboration and endorsements from leading nutrition professional societies, to identify overlaps with syndromes like cachexia and sarcopenia, and to promote dissemination, validation studies, and feedback. The diagnostic construct should be re-considered every 3-5 years.

    更新日期:2019-11-01
  • Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review.
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2019-03-29
    Markus S Anker,Richard Holcomb,Maurizio Muscaritoli,Stephan von Haehling,Wilhelm Haverkamp,Aminah Jatoi,John E Morley,Florian Strasser,Ulf Landmesser,Andrew J S Coats,Stefan D Anker

    BACKGROUND Cachexia has significant impact on the patients' quality of life and prognosis. It is frequently observed in patients with cancer, especially in advanced stages, but prevalence data for the overall population are lacking. Good quality estimates of cancer cachexia in general and for each of the major cancer types would be highly relevant for potential treatment development efforts in this field. Both the USA and European Union (EU) have implemented special clinical development rules for such rare disorders what are called 'orphan diseases'. The cut-off level for a disease to be considered an orphan disease in the USA is 200 000 people (0.06% of the population) and EU is 5 per 10 000 people (0.05% of the population). METHODS For this systematic review, we searched at PubMed (from inception to 31 January 2018) to identify clinical studies that assessed the prevalence of cachexia in cancer patients at risk. Studies reporting the prevalence of either cancer cachexia or wasting disease in the top-10 cancer types and 4 other selected cancer types known to be particularly commonly complicated by cachexia were included in this analysis (i.e. prostate cancer, breast cancer, colorectal cancer, melanoma, endometrial cancer, thyroid cancer, urinary bladder cancer, non-hodgkin lymphoma, lung cancer, kidney and renal pelvis cancer, head and neck cancer, gastric cancer, liver cancer, and pancreatic cancer). We calculated the current burden of cancer cachexia, disease by disease, in the USA and in the EU and compared them to the current guidelines for the definition of orphan disease status. RESULTS We estimate that in 2014 in the USA, a total of 527 100 patients (16.5 subjects per 10 000 people of the total population), and in 2013 in the EU, a total of 800 300 patients (15.8 subjects per 10 000 people of the total population) suffered from cancer cachexia (of any kind). In the 14 separately analysed cancer types, the prevalence of cancer cachexia in the USA ranged between 11 300 (0.4/10 000, gastric cancer) and 92 000 patients (2.9/10 000, lung cancer) and in the EU between 14 300 (0.3/10 000, melanoma of the skin) and 150 100 (3.0/10 000, colorectal cancer). CONCLUSIONS The absolute number of patients affected by cancer cachexia in each cancer group is lower than the defined thresholds for orphan diseases in the USA and EU. Cancer cachexia in each subgroup separately should be considered an orphan disease.

    更新日期:2019-11-01
  • Recent developments in the field of cachexia, sarcopenia, and muscle wasting: highlights from the 11th Cachexia Conference.
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2019-03-29
    Nicole Ebner,Stefan D Anker,Stephan von Haehling

    This article highlights the updates from preclinical and clinical studies into the field of wasting disorders that were presented at the 11th Cachexia Conference held in Maastricht, the Netherlands, in December 2018. Herein, we summarize the biological and clinical significance of different markers and new diagnostic tools and cut-offs for the detection of skeletal muscle wasting, including micro-RNAs, siRNAs, epigenetic targets, the ubiquitin-proteasome system, mammalian target of rapamycin signalling, news in body composition analysis including the D3-creatine dilution method, and electrocardiography that was modified to enable segmental impedance spectroscopy. Of particular interest were the beneficial effects of BIO101 on muscle cell differentiation, hypertrophy of myofibers associated with mammalian target of rapamycin pathways activation, and the effect of metal ion transporter ZIP14 loss that reduces cancer-induced cachexia. The potential of anti-ZIP14 antibodies and zinc chelation as anti-cachexia therapy should be tested in patients with cancer cachexia. Big randomized studies were presented such as RePOWER (observational study of patients with primary mitochondrial myopathy), STRAMBO (influence of physical performance assessed as score and clinical testing), MMPOWER (treatment of elamipretide in subjects with primary mitochondrial myopathy), FORCE (examined differences in relative dose intensity and moderate and severe chemotherapy-associated toxicities between a strength training intervention and a control group), and SPRINTT (effectiveness of exercise training in healthy aging). Effective treatments were urothelin A, rapamycin analogue treatment, epigenetic factor BRD 4 and epigenetic protein BET, and the gut pathobiont Klebsiella oxytoca. Clinical studies that investigated novel approaches, including urolithin A, the role of gut microbiota, metal ion transporter ZIP14, lysophosphatidylcholine and lysophosphatidylethanolamine, and BIO101, were described. It remains a fact, however, that effective treatments of cachexia and wasting disorders are urgently needed in order to improve patients' quality of life and their survival.

    更新日期:2019-11-01
  • 更新日期:2019-11-01
  • Corrigendum.
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2019-10-30

    更新日期:2019-11-01
  • Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2019.
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2019-10-30
    Stephan von Haehling,John E Morley,Andrew J S Coats,Stefan D Anker

    This article details an updated version of the principles of ethical authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle (JCSM) and its two daughter journals JCSM Rapid Communication and JCSM Clinical Reports. We request of all author sending to the journal a paper for consideration that at the time of submission to JCSM, the corresponding author, on behalf of all co-authors, needs to certify adherence to these principles. The principles are as follows: all authors listed on a manuscript considered for publication have approved its submission and (if accepted) approve publication in JCSM as provided; each named author has made a material and independent contribution to the work submitted for publication; no person who has a right to be recognized as author has been omitted from the list of authors on the submitted manuscript; the submitted work is original and is neither under consideration elsewhere nor that it has been published previously in whole or in part other than in abstract form; all authors certify that the submitted work is original and does not contain excessive overlap with prior or contemporaneous publication elsewhere, and where the publication reports on cohorts, trials, or data that have been reported on before the facts need to be acknowledged and these other publications must be referenced; all original research work has been approved by the relevant bodies such as institutional review boards or ethics committees; all relevant conflicts of interest, financial or otherwise, that may affect the authors' ability to present data objectively, and relevant sources of funding of the research in question have been duly declared in the manuscript; the manuscript in its published form will be maintained on the servers of JCSM as a valid publication only as long as all statements in the guidelines on ethical publishing remain true. If any of the aforementioned statements ceases to be true, the authors have a duty to notify as soon as possible the Editors of JCSM, JCSM Rapid Communication, and JCSM Clinical Reports, respectively, so that the available information regarding the published article can be updated and/or the manuscript can be withdrawn.

    更新日期:2019-11-01
  • Is muscle failure a better term than sarcopenia?
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2019-05-22
    Charlotte Suetta,Andrea B Maier

    更新日期:2019-11-01
  • Sarcopenia and mortality among a population-based sample of community-dwelling older adults.
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2016-05-31
    Justin C Brown,Michael O Harhay,Meera N Harhay

    BACKGROUND Sarcopenia is a risk-factor for all-cause mortality among older adults, but it is unknown if sarcopenia predisposes older adults to specific causes of death. Further, it is unknown if the prognostic role of sarcopenia differs between males and females, and obese and non-obese individuals. METHODS A population-based cohort study among 4425 older adults from the Third National Health and Nutrition Survey (1988-1994). Muscle mass was quantified using bioimpedance analysis, and muscle function was quantified using gait speed. Multivariable-adjusted Cox regression analysis examined the relationship between sarcopenia and mortality outcomes. RESULTS The mean age of study participants was 70.1 years. The prevalence of sarcopenia was 36.5%. Sarcopenia associated with an increased risk of all-cause mortality [hazard ratio (HR): 1.29 (95% confidence interval (95% CI): 1.13-1.47); P < 0.001] among males and females. Sarcopenia associated with an increased risk of cardiovascular-specific mortality among females [HR: 1.61 (95% CI: 1.22-2.12); P = 0.001], but not among males [HR: 1.07 (95% CI: 0.81-1.40; P = .643); P interaction = 0.079]. Sarcopenia was not associated with cancer-specific mortality among males and females [HR: 1.07 (95% CI: 0.78-1.89); P = 0.672]. Sarcopenia associated with an increased risk of mortality from other causes (i.e. non-cardiovascular and non-cancer) among males and females [HR: 1.32 (95% CI: 1.07-1.62); P = 0.008]. Obesity, defined using body mass index (P interaction = 0.817) or waist circumference (P interaction = 0.219) did not modify the relationship between sarcopenia and all-cause mortality. CONCLUSIONS Sarcopenia is a prevalent syndrome that is associated with premature mortality among community-dwelling older adults. The prognostic value of sarcopenia may vary by cause-specific mortality and differ between males and females.

    更新日期:2019-11-01
  • Once I get on a puzzle, I can't get off: Cachexia and wasting in 2018.
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2018-11-20
    Stephan von Haehling,Stefan D Anker

    更新日期:2019-11-01
  • Impact of sarcopenia on prognostic value of cirrhosis: going beyond the hepatic venous pressure gradient and MELD score.
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2018-10-30
    Seong Hee Kang,Woo Kyoung Jeong,Soon Koo Baik,Seung Hwan Cha,Moon Young Kim

    BACKGROUND Sarcopenia has been reported as a prognostic factor. We evaluated the impact of sarcopenia to the conventional prognostic factors [Model for End-Stage Liver Disease (MELD) score, Child-Turcotte-Pugh (CTP) score, hepatic venous pressure gradient (HVPG)] in cirrhosis. METHODS Overall, 452 patients with cirrhosis were stratified by MELD score (low < 15, high ≥ 15), CTP class, and HVPG [non-clinically significant portal hypertension (CSPH), 6-9 mmHg; CSPH, 10-19 mmHg; extremely severe PH, ≥20 mmHg]. L3 skeletal muscle index as marker of sarcopenia was subdivided into quartiles (47.01-52.25-58.22 cm2 /m2 ). RESULTS Among the patients, 42% (190/452) presented with sarcopenia. During a median follow-up period of 21.2 months, sarcopenia was associated with mortality (adjusted hazard ratio = 2.253, P < 0.001) and specifically with compensated and early decompensated stages of cirrhosis, but not with advanced decompensated stages; low (P < 0.001) and high (P = 0.095) MELD scores; CTP classes A (P = 0.034), B (P < 0.001), and C (P = 0.205); and non-CSPH (P = 0.018), CSPH (P < 0.001), and extremely severe PH (P = 0.846). In quartiles of sarcopenia, MELD score, CTP class, and HVPG were independent predictors of mortality in non-sarcopenia, but not in severe sarcopenia (MELD, P = 0.182; CTP, P = 0.187; HVPG, P = 0.077). CONCLUSIONS Sarcopenia is associated with mortality in compensated and early decompensated cirrhosis, and existing conventional prognostic factors had limited value in severe sarcopenia. Therefore, incorporating sarcopenia in the conventional prognostic factors had added value, particularly in compensated and early decompensated cirrhosis. Subclassification of prognostic factors according to sarcopenia may help to better assess the prognosis of cirrhosis.

    更新日期:2019-11-01
  • Time to jump on the bandwagon: the Journal of Cachexia, Sarcopenia and Muscle in 2018.
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2018-10-13
    Stephan von Haehling,Markus S Anker,Nicole Ebner,Stefan D Anker

    更新日期:2019-11-01
  • 更新日期:2019-11-01
  • MicroRNAs in muscle wasting.
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2019-01-31
    Tsuyoshi Suzuki,Jochen Springer

    更新日期:2019-11-01
  • 更新日期:2019-11-01
  • Cachexia as a common characteristic in multiple chronic disease.
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2019-01-15
    Nadja Scherbakov,Wolfram Doehner

    更新日期:2019-11-01
  • The Journal of Cachexia, Sarcopenia and Muscle in 2019.
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2019-08-28
    Stephan von Haehling,Nicole Ebner,Stefan D Anker

    更新日期:2019-11-01
  • Corrigendum.
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2019-06-28

    更新日期:2019-11-01
  • Comment on: "Fibroblast growth factor 21 controls mitophagy and muscle mass" by Oost et al.
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2019-07-16
    Yeshun Wu,Bin Zhu,Zijun Chen,Jiahao Duan,Ling Yang

    更新日期:2019-11-01
  • From meta-analysis to Cochrane reviews.
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2018-06-07
    Nicole Ebner,Maciej Banach,Stefan D Anker,Stephan von Haehling

    更新日期:2019-11-01
  • Sarcopenic obesity: time to target the phenotypes.
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2019-04-04
    Simone Perna,Daniele Spadaccini,Mariangela Rondanelli

    更新日期:2019-11-01
  • 更新日期:2019-11-01
  • The authors reply: Letter on: "Pitfalls in the measurement of muscle mass: a need for a reference standard" by Clark et al.
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2019-01-31
    Fanny Buckinx,Francesco Landi,Matteo Cesari,Roger A Fieding,Marjolein Visser,Klaus Engelke,Stefania Maggi,Elaine Dennison,Nasser M Al-Daghri,Sophie Allepaerts,Jurgen Bauer,Ivan Bautmans,Maria-Luisa Brandi,Olivier Bruyère,Tommy Cederholm,Francesca Cerreta,Antonio Cherubini,Cyrus Cooper,Alphonso Cruz-Jentoft,Eugene McCloskey,Bess Dawson-Hughes,Jean-Marc Kaufman,Andrea Laslop,Jean Petermans,Jean-Yves Reginster,René Rizzoli,Sian Robinson,Yves Rolland,Ricardo Rueda,Bruno Vellas,John A Kanis

    However, semantics aside, we think that DXA can indeed serve as a reference standard for measuring muscle mass. Obviously, CT and MRI are advanced techniques that can and have been used to obtain important information such as muscle size/volume and more recently amount and distribution of intra- and intermuscular adipose tissue. Also individual muscles can be assessed separately. However, with respect to muscle mass, the comparison of DXA with CT/MRI is rather difficult because DXA and QCT/MRI measure different physical parameters.

    更新日期:2019-11-01
  • Comment on: "Pitfalls in the measurement of muscle mass: a need for a reference standard" by Buckinx et al.
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2019-01-27
    Brian C Clark,Dallin Tavoian,Bret H Goodpaster,Peggy M Cawthon,Ross D Hansen,Todd M Manini

    更新日期:2019-11-01
  • The Authors reply: "Dual energy X-ray absorptiometry: gold standard for muscle mass?" by Scafoglieri et al.
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2018-08-16
    Fanny Buckinx,Francesco Landi,Matteo Cesari,Roger A Fieding,Marjolein Visser,Klaus Engelke,Stefania Maggi,Elaine Dennison,Nasser M Al-Daghri,Sophie Allepaerts,Jurgen Bauer,Ivan Bautmans,Maria Luisa Brandi,Olivier Bruyère,Tommy Cederholm,Francesca Cerreta,Antonio Cherubini,Cyrus Cooper,Alphonso Cruz-Jentoft,Eugene McCloskey,Bess Dawson-Hughes,Jean-Marc Kaufman,Andrea Laslop,Jean Petermans,Jean-Yves Reginster,René Rizzoli,Sian Robinson,Yves Rolland,Ricardo Rueda,Bruno Vellas,John A Kanis

    更新日期:2019-11-01
  • Dual energy X-ray absorptiometry: gold standard for muscle mass?
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2018-05-23
    Aldo Scafoglieri,Jan Pieter Clarys

    更新日期:2019-11-01
  • Erratum to: Ventricular assist device implantation improves skeletal muscle function, oxidative capacity, and growth hormone/insulin-like growth factor-1 axis signaling in patients with advanced heart failure.
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2014-09-12
    Tuba Khawaja,Aalap Chokshi,Ruiping Ji,Tomoko S Kato,Katherine Xu,Cynthia Zizola,Christina Wu,Daniel E Forman,Takeyoshi Ota,Peter J Kennel,Hiroo Takayama,Yoshifumi Naka,Isaac George,Donna Mancini,P Christian Schulze

    更新日期:2019-11-01
  • Ventricular assist device implantation improves skeletal muscle function, oxidative capacity, and growth hormone/insulin-like growth factor-1 axis signaling in patients with advanced heart failure.
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2014-08-08
    Tuba Khawaja,Aalap Chokshi,Ruiping Ji,Tomoko S Kato,Katherine Xu,Cynthia Zizola,Christina Wu,Daniel E Forman,Takeyoshi Ota,Peter Kennel,Hiroo Takayama,Yoshifumi Naka,Isaac George,Donna Mancini,Christian P Schulze

    BACKGROUND Skeletal muscle dysfunction in patients with heart failure (HF) has been linked to impaired growth hormone (GH)/insulin-like growth factor (IGF)-1 signaling. We hypothesized that ventricular assist device (VAD) implantation reverses GH/IGF-1 axis dysfunction and improves muscle metabolism in HF. METHODS Blood and rectus abdominis muscle samples were collected during VAD implantation and explantation from patients with HF and controls. Clinical data were obtained from medical records, biomarkers measured by enzyme-linked immunosorbent assay (ELISA), and gene expression analyzed by reverse transcription and real-time polymerase chain reaction (RT-PCR). Grip strength was assessed by dynamometry. Oxidative capacity was measured using oleate oxidation rates. Muscle fiber type and size were assessed by histology. RESULTS Elevated GH (0.27 ± 0.27 versus 3.6 ± 7.7 ng/ml in HF; p = 0.0002) and lower IGF-1 and insulin-like growth factor binding protein (IGFBP)-3 were found in HF (IGF-1, 144 ± 41 versus 74 ± 45 ng/ml in HF, p < 0.05; and IGFBP-3, 3,880 ± 934 versus 1,935 ± 862 ng/ml in HF, p = 0.05). The GH/IGF-1 ratio, a marker of GH resistance, was elevated in HF (0.002 ± 0.002 versus 0.048 ± 0.1 pre-VAD; p < 0.0039). After VAD support, skeletal muscle expression of IGF-1 and IGFBP-3 increased (10-fold and 5-fold, respectively; p < 0.05) accompanied by enhanced oxidative gene expression (CD36, CPT1, and PGC1α) and increased oxidation rates (+1.37-fold; p < 0.05). Further, VAD implantation increased the oxidative muscle fiber proportion (38 versus 54 %, p = 0.031), fiber cross-sectional area (CSA) (1,005 ± 668 versus 1,240 ± 670 μm(2), p < 0.001), and Akt phosphorylation state in skeletal muscle. Finally, hand grip strength increased 26.5 ± 27.5 % at 180 days on-VAD (p < 0.05 versus baseline). CONCLUSION Our data demonstrate that VAD implantation corrects GH/IGF-1 signaling, improves muscle structure and function, and enhances oxidative muscle metabolism in patients with advanced HF.

    更新日期:2019-11-01
  • Erratum to: Assessing sarcopenic prevalence and risk factors in residential aged care: methodology and feasibility.
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2014-06-06
    Timothy R Henwood,Justin W Keogh,Natasha Reid,Will Jordan,Hugh E Senior

    更新日期:2019-11-01
  • Assessing sarcopenic prevalence and risk factors in residential aged care: methodology and feasibility.
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2014-04-17
    Timothy R Henwood,Justin W Keogh,Natasha Reid,Will Jordan,Hugh E Senior

    BACKGROUND Sarcopenia is a significant geriatric syndrome with both health care expenditure and personal burden. Most recently, the European Working Group in Sarcopenia in Older Adults has established a consensus definition and assessment criteria for sarcopenia that includes a below-normal muscle mass and muscle function (either or both of below-normal muscle strength and physical performance). Using these criteria, work is needed to identify the prevalence and risk factors among the old, and those most susceptible to sarcopenia, the very old. This manuscript describes the recruitment and data collection methodology, and direct burden to participants, among a very old cohort residing in a residential aged care (RAC) setting. METHODS Eleven RAC facilities participated in the study. Potential participants were identified by the facility service manager and then randomised into the study. All participants gave self or substitute decision maker consent. Participants undertook a single one on one assessment that included measures of sarcopenia, functional capacity, cognitive and nutritional health, falls, activity, facility and hospital history, physical activity and assessment burden. A sub-study of physical activity and sedentary behaviours measured by activPAL3™ inclinometer was also conducted. RESULTS Of 709 residents, 328 were ineligible to participate. Two hundred and seventy-three residents were randomised to the study and 102 gave informed or substitute decision maker consent. Participants were 84.5 ± 8.2 years of age and had been in care for 1,204.2 ± 1,220.1 days. The groups need for care was high (Aged Care Funding Instrument score of 2.6 ± 1.7) and they had a below-normal functional (Short Physical Performance Battery summery score of 3.5 ± 2.4). The larger percentage of participants had no depression and normal cognitive capacity. A total of 33 residents participated in the activPAL study. Each assessment took an average of 27.0 ± 7.0 min, with a low assessment burden reported by participants. CONCLUSIONS The successful assessment of sarcopenia and physical activity in a RAC setting is labour intensive to establish, but feasible to conduct. Low recruitment numbers and the restrictive exclusion criteria, may have limited the accuracy of this work. However, this work is a primary step in establishing the level of sarcopenia and its risk factors for those in end-of-life care.

    更新日期:2019-11-01
  • Erratum to: Recent developments in the treatment of cachexia: highlights from the 6th Cachexia Conference.
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2012-05-23
    N Ebner,C G Werner,W Doehner,S D Anker,S von Haehling

    更新日期:2019-11-01
  • Recent developments in the treatment of cachexia: highlights from the 6th Cachexia Conference.
    J. Cachexia Sarcopenia Muscle (IF 10.754) Pub Date : 2012-03-31
    Nicole Ebner,Claudia G Werner,Wolfram Doehner,Stefan D Anker,Stephan von Haehling

    更新日期:2019-11-01
Contents have been reproduced by permission of the publishers.
导出
全部期刊列表>>
2020新春特辑
限时免费阅读临床医学内容
ACS材料视界
科学报告最新纳米科学与技术研究
清华大学化学系段昊泓
自然科研论文编辑服务
中国科学院大学楚甲祥
中国科学院微生物研究所潘国辉
中国科学院化学研究所
课题组网站
X-MOL
北京大学分子工程苏南研究院
华东师范大学分子机器及功能材料
中山大学化学工程与技术学院
试剂库存
天合科研
down
wechat
bug